Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Uro
Special Issues
Urologic Oncology: Analysis and Treatment
share announcement

Urologic Oncology: Analysis and Treatment

A special issue of Uro (ISSN 2673-4397).

Deadline for manuscript submissions: 15 July 2024 | Viewed by 1357

Special Issue Editor

Dr. Haoyue Sheng

E-Mail Website
Guest Editor
Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
Interests: prostate cancer; bladder cancer; renal cancer

Special Issue Information

Dear Colleagues,

"Urologic Oncology: Analysis and Treatment" is a Special Issue dedicated to the study and management of cancers affecting the urinary system, including the kidneys, bladder, prostate, and related organs. The Special Issue’s core focus is to provide a platform for researchers and clinicians to share their latest findings and experiences in urologic oncology. It encompasses a wide range of topics, from epidemiology and diagnostics to various treatment modalities (surgery, radiation, chemotherapy, and immunotherapy) and their outcomes.

This Special Issue situates itself within the existing urologic oncology literature by contributing new research, clinical insights, and perspectives. Authors are encouraged to reference relevant studies and guidelines, aligning their work with the field's latest developments and best practices. The goal is to foster knowledge exchange, enhancing patient care and outcomes in urologic oncology. Ultimately, this Special Issue advances the field by facilitating idea sharing, methodologies, and experiences among experts. It supports ongoing improvements in urologic cancer management while providing a valuable resource for the broader medical and research community.

Dr. Haoyue Sheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Uro is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urologic oncology
  • cancer treatment
  • urinary system
  • kidney cancer
  • bladder cancer
  • prostate cancer
  • diagnosis and screening
  • treatment modalities

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 755 KiB  
Article
The Value of Adding Exosome-Based Prostate Intelliscore to Multiparametric Magnetic Resonance Imaging in Prostate Biopsy: A Retrospective Analysis
by Noah King, Jacob Lang, Sree Jambunathan, Conner Lombardi, Barbara Saltzman, Nadiminty Nagalakshmi and Puneet Sindhwani
Uro 2024, 4(2), 50-59; https://0-doi-org.brum.beds.ac.uk/10.3390/uro4020005 - 8 May 2024
Viewed by 220
Abstract
Introduction: Currently, there is limited evidence for the relationship of Exosome-based Prostate Intelliscore (EPI) and multiparametric magnetic resonance imaging (mpMRI) in stratifying risk for clinically significant prostate cancer. Using a retrospective cohort study design, we sought to characterize the relationship between these two [...] Read more.
Introduction: Currently, there is limited evidence for the relationship of Exosome-based Prostate Intelliscore (EPI) and multiparametric magnetic resonance imaging (mpMRI) in stratifying risk for clinically significant prostate cancer. Using a retrospective cohort study design, we sought to characterize the relationship between these two noninvasive metrics and prostate biopsy outcome. Methods: Data were collected via electronic medical record for all patients who underwent EPI testing from 1 January 2019 to 3 February 2022 and had available medical records at a single mid-western university medical center. Positive test result was defined as >15.6 for EPI, ≥3 PI-RADS score and ≥3 + 4 Gleason Score for biopsy findings. Utility of EPI, mpMRI and combined use was characterized through calculation of sensitivity, specificity, positive predictive value, negative predictive value, and ROC analysis. Results: A total of 226 patients were identified as receiving EPI testing for risk stratification of clinically significant prostate cancer. Sensitivity for EPI was 91%, mpMRI was 90%, and the highest was combined use at 96%. With ROC analysis, AUC for EPI alone was 0.57 (95% CI, 0.47–0.67) and 0.78 (95% CI, 0.70–0.87) for mpMRI alone. With prior positive EPI result, AUC for combined use with mpMRI was 0.80 (95% CI, 0.71–0.89). Further subgroup analysis resulted in increased AUC values of EPI 0.67 (95% CI, 0.48–0.87), mpMRI 0.90 (95% CI, 0.76–1.0), and combined 0.90 (95% CI, 0.75–1.0) in the African American population. Discussion: We observed that the combined use of EPI and mpMRI led to an avoided biopsy in 43% of patients. Using both parameters increased the overall sensitivity and diagnostic accuracy in detecting clinically significant prostate cancer. The best test performance was observed in the African American cohort. Identifying optimal noninvasive tools to assess risk for prostate cancer is crucial to providing accurate and cost-effective care. Future study should utilize a prospective study design to further support the combined use of these metrics. Full article
(This article belongs to the Special Issue Urologic Oncology: Analysis and Treatment)
►▼ Show Figures

Figure 1

11 pages, 1503 KiB  
Article
An Exploratory Study of Early Immune Response Markers for Pembrolizumab in Urothelial Tract Cancer
by Dag Rune Stormoen, Lise Høj Omland, Kent William Mouw, Zoltan Szallasi, Sisse Rye Ostrowski, Susanne Dam Nielsen and Helle Pappot
Uro 2024, 4(1), 1-11; https://0-doi-org.brum.beds.ac.uk/10.3390/uro4010001 - 12 Jan 2024
Viewed by 857
Abstract
Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated metastatic urothelial tract cancer (mUTC) patients as the study population. Methods: We included ten [...] Read more.
Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated metastatic urothelial tract cancer (mUTC) patients as the study population. Methods: We included ten mUTC patients and assessed their innate immune responses before the first and second pembrolizumab cycles with the TruCulture® immunoassay. We also executed survival analysis and compared cytokine release. Results: R848-induced IFNα and HKCA-induced IL-10 values decreased in patients with disease progression (n = 7), while these values increased in non-progressing patients (n = 3), denoting a significant difference (p = 0.00192 and p = 0.00343, respectively). Further, an increased R848-induced IFNα response correlated with extended survival (log-rank p-value of 0.048). Conclusion: Our small study identified distinct immune response patterns following pembrolizumab’s first cycle in mUTC patients, hypothesizing the potential of an increased R848-induced IFNα response for improved survival outcomes. Further confirmatory studies are in progress. Full article
(This article belongs to the Special Issue Urologic Oncology: Analysis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop